Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults

Next Previous
Search
Trial Profile

A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tavaborole (Primary)
  • Indications Onychomycosis
  • Focus Therapeutic Use
  • Sponsors Anacor Pharmaceuticals; Pfizer

    • Most Recent Events

    • 08 Jul 2014 Results published in an Anacor Pharmaceuticals media release.
    • 08 Jul 2014 Primary endpoint 'Complete cure' has been met according to an Anacor Pharmaceuticals media release.
    • 08 Jul 2014 According to an Anacor Pharmaceuticals media release, the US FDA has approved tavaborole for the topical treatment of onychomycosis of the toenails on the basis of results from this an another trial (see CT profile 244682).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top